BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 11709773)

  • 1. Vaccine industry perspective of current issues of good manufacturing practices regarding product inspections and stability testing.
    Monahan TR
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S356-61. PubMed ID: 11709773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manufacturing issues with combining different antigens: a regulatory perspective.
    Falk LA; Arciniega J; McVittie L
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S351-5. PubMed ID: 11709772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparing for an FDA preapproval inspection.
    Blackmer RA
    Qual Assur; 1994 Dec; 3(4):389-403. PubMed ID: 7613749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and approval of vaccines in the United States.
    Botstein P
    Isr J Med Sci; 1986; 22(3-4):268-71. PubMed ID: 3528047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Food and Drug Administration regulation and evaluation of vaccines.
    Marshall V; Baylor NW
    Pediatrics; 2011 May; 127 Suppl 1():S23-30. PubMed ID: 21502242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten steps to ensure a successful preNDA approval inspection.
    Justice RM; Rodriguez JO; Chiasson WJ
    J Parenter Sci Technol; 1993; 47(2):89-92. PubMed ID: 8515350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manufacturing issues related to combining different antigens: an industry perspective.
    Van Hoof J
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S346-50. PubMed ID: 11709771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory expectations during product development for tumour vaccines.
    Kawakami K; Puri RK
    Dev Biol (Basel); 2004; 116():53-9; discussion 69-76. PubMed ID: 15603183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Food and Drug Administration inspection and licensing of manufacturing facilities.
    Avallone HL; Beatrice MG; Sze TT
    Bioprocess Technol; 1991; 13():315-40. PubMed ID: 1367137
    [No Abstract]   [Full Text] [Related]  

  • 11. Current good manufacturing practices for PET drug products in the United States.
    Swanson D; Graham M; Heinonen TM; Libby P; Mills GQ
    J Nucl Med; 2009 Aug; 50(8):26N-8N. PubMed ID: 19652213
    [No Abstract]   [Full Text] [Related]  

  • 12. Review of current preclinical testing strategies for bacterial vaccines.
    Falk LA; Chandler DK; Richman P
    Dev Biol Stand; 1998; 95():25-9. PubMed ID: 9855411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of total quality principles to achieve regulatory compliance in research laboratories.
    Hynes MD
    Qual Assur; 1995 Mar; 4(1):34-40. PubMed ID: 8520863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory requirements for veterinary vaccine stability in the European Community.
    Fawthrop D
    Dev Biol Stand; 1996; 87():319-27. PubMed ID: 8854032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories.
    Jimenez FA
    Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711
    [No Abstract]   [Full Text] [Related]  

  • 16. Regulatory harmonization--a vaccine industry perspective.
    Goodrich TD
    Dev Biol Stand; 1997; 90():355-61. PubMed ID: 9270864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on the manufacture of combination vaccines.
    Vose JR
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S334-9. PubMed ID: 11709769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of gene therapy products and the impact of manufacturing changes on product comparability.
    Simek SL
    Dev Biol (Basel); 2005; 122():139-44. PubMed ID: 16375258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies.
    Kanesa-thasan N; Shaw A; Stoddard JJ; Vernon TM
    Pediatrics; 2011 May; 127 Suppl 1():S16-22. PubMed ID: 21502248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Instrumentation and radiopharmaceutical validation.
    Zigler SS
    Q J Nucl Med Mol Imaging; 2009 Aug; 53(4):402-10. PubMed ID: 19834450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.